Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Investing.com -- Le azioni di Travere Therapeutics Inc ( NASDAQ:TVTX) sono scese fino al 2,3% nelle contrattazioni ...
Det bemærker aktiechef i Sampension, Philip Jagd, som også påpeger, at aktien nu befinder sig i det laveste niveau siden ...
Ligand agreed to acquire royalty and milestone rights for Santen’s Ryjunea eye drop for $23 million upfront, expanding its ...
TravereTherapeutics: Eric Dube, Ph.D., to Step Down as Pres and CEO in Dec >TVTX ...
TravereTherapeutics: Bradley Campbell to Be Appointed Pres and CEO, Effective Dec 1 >TVTX ...
Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.
1h
Teva Pharmaceutical Industries Insider Sold Shares Worth $285,215, According to a Recent SEC Filing
Brian Savage, Interim Chief Legal Officer, on September 18, 2026, sold 7,342 shares in Teva Pharmaceutical Industries (TEVA) for $285,215. Following the Form 4 filing with the SEC, Savage has control ...
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on ...
The Gabelli Healthcare & Wellness Trust is a diversified, closed-end management investment company whose investment objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results